  Variability in drug efficacy and adverse effects are observed in clinical
practice. While the extent of genetic variability in classical pharmacokinetic
genes is rather well understood, the role of genetic variation in drug targets
is typically less studied. Based on 60,706 human exomes from the ExAC dataset,
we performed an in-depth computational analysis of the prevalence of
functional-variants in in 806 drug-related genes, including 628 known drug
targets. We find that most genetic variants in these genes are very rare (f <
0.1%) and thus likely not observed in clinical trials. Overall, however, four
in five patients are likely to carry a functional-variant in a target for
commonly prescribed drugs and many of these might alter drug efficacy. We
further computed the likelihood of 1,236 FDA approved drugs to be affected by
functional-variants in their targets and show that the patient-risk varies for
many drugs with respect to geographic ancestry. A focused analysis of
oncological drug targets indicates that the probability of a patient carrying
germline variants in oncological drug targets is with 44% high enough to
suggest that not only somatic alterations, but also germline variants carried
over into the tumor genome should be included in therapeutic decision-making.
